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A B S T R A C T
A 16% decline in rates of penicillin resistance
in Streptococcus pneumoniae isolates in Taiwan
between 1998–1999 (25%) and 2001 (9%) was
associated with a 46% decrease in total penicillin
and other cephalosporin usage in 2001 compared
with 1999. However, erythromycin resistance in
S. pneumoniae remained high (94%), despite a
45% decrease in macrolide consumption between
1999 and 2001.
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Taiwan has one of the highest levels of antibiotic
resistance in the world [1] and, since 1996, has also
become one of the epicentres for pneumococcal
resistance to penicillin and macrolides [2–4]. A
nationwide surveillance system (Surveillance of
Multicentre Antimicrobial Resistance; SMART)
has monitored antimicrobial resistance since 1998
[1,2]. Many measures to address high resistance
rates, including enforcement of prescription-fill-
ing practices in the pharmacy (starting in 1997)
and educational programmes dealing with appro-
priate antibiotic use (starting in 1998), have been
instituted. Surveillance of antimicrobial resistance
and strict control of antibiotic usage are important
objectives for the Department of Health [1,2,5].
In February 2001, a new regulation was intro-
duced, under which the costs of antimicrobial
agents used in treatment of ambulatory patients
with acute upper respiratory tract infections
without evidence of bacterial involvement are not
reimbursed [5].
Use (defined daily doses (DDDs) ⁄ 1000 popula-
tion ⁄day) of antimicrobial agents in treatment of
ambulatory patients decreased by 11% in 2000
compared with 1999 (26.5 vs. 29.7 DDDs), and,
following implementation of the regulation, by a
further 25% in 2001 compared with 2000 (26.5 vs.
19.8 DDDs) [5]. There was an 11% reduction in the
use of antimicrobial agents for treating respiratory
tract infections (including upper respiratory tract
infections and non-upper respiratory tract infec-
tions) in 2000 compared with 1999 (16.1 vs.
18.0 DDDs), and a further 38% reduction in
2001 compared with 2000 (18.0 vs. 10.0 DDDs)
[5]. Use of penicillins and cephalosporins in
treatment of ambulatory patients declined from
15.7 DDDs ⁄ 1000 population ⁄day in 1999, to 14.0 in
2000, and 8.5 in 2001, while use of macrolides
declined from 2.9 DDDs ⁄ 1000 population ⁄day in
1999, to 2.5 in 2000, and 1.6 in 2001. In addition,
overall reductions of 46% and 45% occurred in the
use of penicillins ⁄ cephalosporins and macrolides,
respectively, in 2001 compared with 1999. Use
of quinolones was 0.59, 0.61 and 0.51 DDDs ⁄
1000 population ⁄day in 1999, 2000 and 2001,
respectively [5].
Fig. 1 shows the annual incidences of penicil-
lin-non-susceptible (zone diameter around a 1 lg-
oxacillin disk of £ 19 mm, with corresponding
MICs of ‡ 0.12 mg ⁄L) Streptococcus pneumoniae
and erythromycin-resistant S. pneumoniae among
the 2362 clinical isolates of S. pneumoniae tested
between 1984 and 2003 at the National Taiwan
University Hospital with the standard disk-diffu-
sion method. The isolation frequency of penicil-
lin-non-susceptible S. pneumoniae increased
markedly from 1993, with a peak of 86% in
1999, and subsequently declined to 70% in 2003.
In contrast, stepwise increases in the frequency of
erythromycin-resistant S. pneumoniae occurred
after 1984, exceeding 90% by 1997, and reaching
a plateau of 94% between 2001 and 2003.
Fig. 2 shows the frequency of isolation of
penicillin-sensitive, -intermediate and -resistant,
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as well as erythromycin-resistant, clinical isolates
of S. pneumoniae, as determined by agar dilution,
in the periods November 1998 to May 1999,
January 2000 to December 2000, January 2001 to
December 2001, and August 2003 to December
2003. These isolates were from various clinical
samples received at multiple medical centres
participating in the SMART programme in differ-
ent regions of Taiwan. The decrease in the
frequency of penicillin resistance among S. pneu-
moniae isolates between 1999 and 2001 was asso-
ciated significantly with the decreased use of
penicillin and cephalosporins (r = 0.8008 (Pear-
son’s correlation coefficient); p 0.4088) and macro-
lides (r = 0.8446; p 0.3596).
A left shift of the penicillin MIC distribution
with time was also noted, with MIC50s of 1 mg ⁄L,
1 mg ⁄L, 0.5 mg ⁄L and 0.5 mg ⁄L, and MIC90s of
4 mg ⁄L, 2 mg ⁄L, 2 mg ⁄L and 1 mg ⁄L, respect-
ively, in isolates from 1998 to 1999, 2000, 2001 and
2003. Among the erythromycin-resistant isolates
collected in these periods, 60–67% exhibited
high-level resistance to erythromycin (MICs
> 64 mg ⁄L) [3,4]. Increasing rates of resistance to
levofloxacin (MICs ‡ 8 mg ⁄L) in these four peri-
ods were also observed, from 0.4% (one isolate),
to 1.0% (two isolates), 0.4% (three isolates), and
2.6% (five isolates) [3,4].
Differential selective pressure for resistance
and dissemination of resistant clones is thought
to be responsible for geographical and chronolo-
gical differences in resistance rates [6]. In Canada,
a 20% decline in penicillin-non-susceptible
S. pneumoniae isolates was noted between 1997–
1998 and 2000–2001, corresponding to a 14%
decline in total antibiotic consumption [7]. Other
studies from the USA and several European
countries have indicated that rates of penicillin
and macrolide non-susceptibility among pneu-
mococcal isolates collected after 2000 have stabi-
lised, or even decreased, compared with trends in
the early 1990s [7]. However, using active sur-
veillance data for S. pneumoniae isolates in the
USA, McCormick et al. [6] observed a decline in
the proportion of isolates resistant to penicillin
alone between 1996 and 2004, but a rise in
erythromycin resistance during the same period
[6]. Moreover, some of the success in reducing
rates of non-susceptibility to penicillin or macro-
lides may have come at the expense of increasing
resistance to fluoroquinolones, probably associ-
ated directly with increased use of these agents
for the treatment of respiratory tract infections,
because of the fear of growing penicillin and
macrolide resistance [7]. In Taiwan, although data
regarding antibiotic consumption during 2003 are
not yet available, the use of fluoroquinolones is
expected to have increased following the recent
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Fig. 1. Trend of decreased susceptibility to penicillin
(PNSSP) and erythromycin (ERSP) among Streptococcus
pneumoniae isolates recovered at the National Taiwan
University Hospital between 1984 and 2003. The black
arrow indicates the year when the National Health
Insurance non-reimbursement policy for restriction of
antibiotic use was implemented.
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Fig. 2. Frequency of three categories
of susceptibility to penicillin and
resistance to erythromycin among
Streptococcus pneumoniae isolates
collected from multiple medical
centres in Taiwan. The black arrow
indicates the year when the National
Health Insurance non-reimburse-
ment policy for restriction of
antibiotic use was implemented.
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introduction of newer agents (levofloxacin in 2001
and moxifloxacin in 2002).
Rates of resistance decline appear to be slower
than rates of resistance emergence, and appear to
vary with different classes of agent. Appropriate
use of antimicrobial agents appears to be the most
important factor in limiting the spread of drug
resistance among pneumococci. In Taiwan, the
decreasing selective pressure for resistance, associ-
ated with a government policy of restricting anti-
biotic use for acute respiratory tract infections
without evidence of bacterial involvement, has
resulted in a decline in erythromycin resistance in
Streptococcuspyogenes [8] andinpenicillin resistance
in pneumococci; however, the impact of this policy
on macrolide resistance in S. pneumoniae is not yet
clear. The present results indicate that continuous
enforcement of the policy to limit use of antimicro-
bial agents is warranted. Such programmes may
protect the effectiveness of newer antimicrobial
agents and limit the emergence of resistance. Active
surveillance of antimicrobial resistance through a
nationwide system, and use of better anti-pneumo-
coccal vaccines, are also required.
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A B S T R A C T
In total, 124 Streptococcus pyogenes isolates were
obtained from throat cultures of different symp-
tomatic patients. All isolates showed M-pheno-
type macrolide resistance and contained the
macrolide efflux gene mef(A). The isolates were
screened for the presence and insertion site of
mef(A)-containing genetic elements. In 25.8% of
the isolates, mef(A) was found to be carried by
elements belonging to the Tn1207.3 ⁄ F10394.4
family inserted in the comEC gene, while 74.2%
contained chimeric elements with a different
genetic structure and chromosomal location,
probably associated with the recently described
60-kb tet(O)–mef(A) element.
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The acquisition of erythromycin resistance by
group A streptococci (Streptococcus pyogenes) is
associated frequently with an efflux system that
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